SOPHiA GENETICS SA (SOPH)

NASDAQ: SOPH · IEX Real-Time Price · USD
11.86 -2.28 (-16.10%)
Jan 18, 2022 2:00 PM EST - Market open
Market Cap757.03M
Revenue (ttm)37.35M
Net Income (ttm)-62.78M
Shares Out63.86M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume170,896
Open14.13
Previous Close14.13
Day's Range11.68 - 14.24
52-Week Range11.54 - 19.80
Betan/a
AnalystsBuy
Price Target23.00 (+94.0%)
Earnings DateNov 10, 2021

About SOPH

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. We purposefully built a cloud-based software-as-a-service (“SaaS”) platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. Our platform standardizes, computes and analyzes digital health data and is used across decentralized locations to break down data silos. This enables healthcare institutions to s...

IndustryHealth Information Services
IPO DateJul 23, 2021
CEOJurgi Camblong
Employees415
Stock ExchangeNASDAQ
Ticker SymbolSOPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SOPH stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 94.01% from the latest price.

Price Target
$23.00
(94.01% upside)
Analyst Consensus: Buy

News

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine,...

1 week ago - PRNewsWire

Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business

BOSTON and LAUSANNE, Switzerland, Jan. 10, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine,...

1 week ago - PRNewsWire

SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Offic...

2 weeks ago - GlobeNewsWire

SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study

Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients wi...

1 month ago - PRNewsWire

SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021

Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare all...

1 month ago - PRNewsWire

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), ...

2 months ago - PRNewsWire

SOPHiA GENETICS to Participate in Upcoming November Investor Conferences

BOSTON and LAUSANNE, Switzerland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced the company will be participating virtually in the following investor conferences:

2 months ago - GlobeNewsWire

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on...

2 months ago - GlobeNewsWire

SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases

BOSTON and LAUSANNE, Switzerland, Oct. 12, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine,...

3 months ago - PRNewsWire

SOPHiA GENETICS Reports Second Quarter 2021 Financial Results and Issues 2021 Guidance

BOSTON and LAUSANNE, Switzerland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021.

4 months ago - GlobeNewsWire

SOPHiA GENETICS to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthca...

4 months ago - GlobeNewsWire

UPDATE – SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021

BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the second quarter of 2021 before market open o...

4 months ago - GlobeNewsWire

SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021

BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the second quarter of 2021 before market open o...

4 months ago - GlobeNewsWire

Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Lati...

SÃO PAULO, Brazil and BOSTON, Aug. 24, 2021 /PRNewswire/ -- Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to...

4 months ago - PRNewsWire

SOPHiA GENETICS Announces Closing of $234 Million Initial Public Offering and $20 Million Private Placement

BOSTON and LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medic...

5 months ago - GlobeNewsWire

SOPHiA Genetics set to go public at a $1.1 billion valuation

SOPHiA Genetics SA is set up for a public debut Friday, as the Switzerland-based data-driven medicine company's initial public offering price overnight at $18 a share, which was in the middle of the exp...

5 months ago - Market Watch

AI-based Healthcare Data Analytics Platform Provider Sophia Genetics Makes Its Wall Street Debut: What You Need to Know

Switzerland-based Sophia Genetics SA (NASDAQ: SOPH), a healthcare tech company, is debuting on Wall Street Friday. Here is what you should know about the company.

5 months ago - Benzinga

SOPHiA GENETICS Announces Pricing of Initial Public Offering

BOSTON and LAUSANNE, Switzerland, July 22, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced ...

5 months ago - GlobeNewsWire